FY2025 EPS Forecast for Fate Therapeutics Boosted by Analyst

Fate Therapeutics, Inc. (NASDAQ:FATE) – Analysts at Cantor Fitzgerald boosted their FY2025 EPS estimates for Fate Therapeutics in a note issued to investors on Tuesday, March 18th. Cantor Fitzgerald analyst L. Watsek now anticipates that the biopharmaceutical company will post earnings per share of ($1.20) for the year, up from their previous forecast of ($1.67). The consensus estimate for Fate Therapeutics’ current full-year earnings is ($1.63) per share.

Fate Therapeutics (NASDAQ:FATE) last announced its quarterly earnings data on Wednesday, March 5th. The biopharmaceutical company reported ($0.31) EPS for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.13. Fate Therapeutics had a negative net margin of 1,325.43% and a negative return on equity of 45.88%. The firm had revenue of $1.86 million for the quarter, compared to the consensus estimate of $1.57 million.

A number of other brokerages also recently commented on FATE. StockNews.com downgraded shares of Fate Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, March 11th. Wedbush reaffirmed a “neutral” rating and set a $5.00 price objective on shares of Fate Therapeutics in a research report on Thursday, March 6th. Stifel Nicolaus reduced their target price on shares of Fate Therapeutics from $5.00 to $3.00 and set a “hold” rating for the company in a research note on Thursday, March 6th. Needham & Company LLC reiterated a “hold” rating on shares of Fate Therapeutics in a research note on Thursday, March 6th. Finally, Wells Fargo & Company reduced their target price on shares of Fate Therapeutics from $5.00 to $4.00 and set an “equal weight” rating for the company in a research note on Thursday, March 6th. One analyst has rated the stock with a sell rating, seven have issued a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $5.50.

Fate Therapeutics Stock Performance

Shares of FATE opened at $0.91 on Thursday. The company’s 50 day moving average price is $1.24 and its 200 day moving average price is $2.21. Fate Therapeutics has a 52 week low of $0.87 and a 52 week high of $7.70. The company has a market capitalization of $103.78 million, a PE ratio of -0.55 and a beta of 2.26.

Institutional Trading of Fate Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the company. Vestal Point Capital LP lifted its stake in shares of Fate Therapeutics by 46.3% in the fourth quarter. Vestal Point Capital LP now owns 2,465,000 shares of the biopharmaceutical company’s stock worth $4,067,000 after buying an additional 780,000 shares during the last quarter. Squarepoint Ops LLC lifted its stake in shares of Fate Therapeutics by 154.2% in the fourth quarter. Squarepoint Ops LLC now owns 34,295 shares of the biopharmaceutical company’s stock worth $57,000 after buying an additional 20,805 shares during the last quarter. Tang Capital Management LLC increased its position in Fate Therapeutics by 165.1% during the fourth quarter. Tang Capital Management LLC now owns 1,855,954 shares of the biopharmaceutical company’s stock worth $3,062,000 after acquiring an additional 1,155,954 shares during the period. Sphera Funds Management LTD. bought a new position in Fate Therapeutics during the fourth quarter worth $655,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in Fate Therapeutics during the fourth quarter worth $55,000. 97.54% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Fate Therapeutics

In other news, Director Redmile Group, Llc acquired 397,964 shares of Fate Therapeutics stock in a transaction dated Friday, December 20th. The stock was acquired at an average cost of $1.68 per share, for a total transaction of $668,579.52. Following the completion of the purchase, the director now owns 12,884,277 shares of the company’s stock, valued at $21,645,585.36. This represents a 3.19 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. 5.00% of the stock is owned by corporate insiders.

Fate Therapeutics Company Profile

Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders.